Prior studies suggesting that diabetes drug 'Actos' might raise users' risk of bladder cancer but new study found no evidence for such an effect. Instead, researchers found a link between the use of Actos (pioglitazone) and a rise in pancreatic cancer risk, but experts say it's too early to draw any conclusive link. The study is published in Journal of the American Medical Association.

